The acquisition is the fifth in 18 months for Arcwood, an environmental services firm that until last year operated as Heritage Environmental Services.
Former Indianapolis Colts quarterback Peyton Manning emceed the event, which took place before about 500 attendees at the new Lilly Event Center in downtown Indianapolis.
The Indianapolis-based drugmaker will work to support UNICEF’s efforts to strengthen primary health care systems to prevent, detect and manage noncommunicable diseases in children and adolescents.
There’s no doubt the company has been among Indiana’s greatest innovators, employing tens of thousands of Hoosiers and contributing significantly to our state’s economy.
The nearly $24.3 million project, being led by Bloomington-based Applied Research Institute, or ARI, will serve as a biomanufacturing workforce training and innovation center when complete.
The university’s board of trustees could have a challenging task ahead in finding Mung Chiang’s replacement, given the breadth of the president’s role and Purdue’s standing as one of the largest and most widely respected public research universities in the United States.
The name BioHeartland was created to give Indiana “a more cohesive and unified way to share the state’s story with investors, companies, researchers and talent around the world,” officials said.
The Indianapolis-based company has announced the phased launch of Befrena, a monoclonal antibody injection for treating canine allergic and atopic dermatitis.
Deal after deal, Eli Lilly and Co. is using the fruits of its success from developing blockbuster GLP-1 medicines to prepare for its next chapter and build a bridge over a looming patent cliff.
The Indianapolis drugmaker is purchasing Curevo Inc., LimmaTech Biologics AG and Vaccine Co. Inc. to expand its research and development efforts in infectious disease.
Tens of millions of people are now taking the medications worldwide, turning what began as obesity and diabetes treatments into what could be modern medicine’s largest unplanned neuroscience experiments.
Eli Lilly and Co. this month unveiled startling new data for an experimental weight-loss drug. The breakthrough also is prompting some doctors to urge caution.
BE-101, soon to be known as Optavant, is expected to be commercially available in the third quarter of this year after it receives full licensure from the U.S. Department of Agriculture.
